Crotedumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | GCGR |
Clinical data | |
Other names | REGN1193 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6518H10044N1732O2052S46 |
Molar mass | 146976.88 g·mol−1 |
Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]
This drug was developed by Regeneron Pharmaceuticals but is no longer under development.[3]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ Peterson SM, Hutchings CJ, Hu CF, Mathur M, Salameh JW, Axelrod F, Sato AK (April 2023). "Discovery and design of G protein-coupled receptor targeting antibodies". Expert Opinion on Drug Discovery. 18 (4): 417–428. doi:10.1080/17460441.2023.2193389. PMID 36992620.